Blockchain Registration Transaction Record

BioCorRx Reports 4,306% Revenue Surge with Breakthrough Addiction Treatments

BioCorRx Inc. reports a 4,306% revenue increase in Q2 2025, driven by LUCEMYRA® acquisition and advances in addiction treatment research. Discover how.

The advancements and financial growth reported by BioCorRx Inc. are not just numbers; they represent hope for millions affected by substance abuse and related disorders. The acquisition of LUCEMYRA® and the development of BICX104 could revolutionize treatment options for opioid withdrawal and methamphetamine use disorder, addressing critical gaps in current healthcare solutions. This news matters because it highlights the potential for significant improvements in public health, offering new avenues for treatment and recovery for individuals and families grappling with addiction.